(NYSE: ADCT) Adc Therapeutics Sa's forecast annual revenue growth rate of 24.05% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Adc Therapeutics Sa's revenue in 2025 is $70,837,000.On average, 2 Wall Street analysts forecast ADCT's revenue for 2025 to be $7,473,893,900, with the lowest ADCT revenue forecast at $7,411,471,082, and the highest ADCT revenue forecast at $7,536,316,718. On average, 1 Wall Street analysts forecast ADCT's revenue for 2026 to be $11,553,175,511, with the lowest ADCT revenue forecast at $11,553,175,511, and the highest ADCT revenue forecast at $11,553,175,511.
In 2027, ADCT is forecast to generate $12,900,715,708 in revenue, with the lowest revenue forecast at $12,900,715,708 and the highest revenue forecast at $12,900,715,708.